Hospital Acquired Infection Treatment Market Rides on Increased Prevalence of HAI Worldwide

A hospital-acquired infection (HAI) is also otherwise known as a nosocomial infection. It is a type of infection that is contacted in a healthcare facility or in a hospital. The infection is also known as health care–associated infection in an effort to emphasize on both non-hospital and hospital settings. A rise in the incidences of such an infection is expected to give a boost to the global hospital acquired infection treatment market over the timeframe of projection.

Fungal, bacterial, and viral pathogens cause hospital-acquired infections. The most common types are surgical site infection (SSI), urinary tract infection (UTI), pneumonia (such as ventilator-associated pneumonia), and bloodstream infection (BSI).

Market Growth to be driven by Vulnerability of Newborn Babies toward HAI

In some cases, hospital acquired infection manifests itself weeks after discharge from the hospital though it had been contacted in the hospital. The infection could also infect the hospital staff and caregivers associated with taking care of such patients. Such high prevalence and contagiousness of the infection is likely to spell growth for the global hospital acquired infection treatment market in near future.

Many antimicrobial drugs have proven to be highly effective in treating a wide range of hospital-related infections that are highly prevalent across the globe. Treatments of hospital-acquired infections comprise the following

  • Antifungal therapy
  • Antiviral therapy

The most sterilized sections of the hospital are the neonatal intensive care units (NICUs), which keeps infants as they are more vulnerable to such infections during the span of their hospital stay.  The National Institute of Child Health and Human Development (NICHD) conducted a study titled “Neonatal Network”. The study projected that around 29% of the infants born at 25 to 28 weeks of gestation period and 46% of the newborns born at less than 25 weeks of gestation are estimated to experience severe hospital acquired infection over the period of hospitalization at NICU. High vulnerability of infants likely to play an important role in the development of the global hospital acquired infection treatment market in near future. 

  • According to Transparency Market Research’s latest report on the global hospital acquired infection treatment (HAI) market for the historical period 2017–2018 and forecast period 2019–2027, unhygienic conditions and improper sterilization treatment, lack of surveillance systems for HAIs, high susceptibility of neonatal population, and rising geriatric population are projected to drive the global hospital acquired infection treatment (HAI) market during the forecast period
  • According to the report, the global hospital acquired infection treatment (HAI) market was valued at US$ 31.0 Bn in 2018 and is anticipated to expand at a CAGR of 2.5% from 2019 to 2027
fa global hospital acquired infection treatment market

To know the scope of our report Get a Sample on Hospital Acquired Infection Treatment Market

Rising Geriatric Population and Unhygienic Conditions and Improper Sterilization Treatment: Key Drivers

  • Continuous increase in the geriatric population is expected to be one of the potential drivers of the hospital acquired infection (HAI) treatment market during the forecast period. The geriatric population is at high risk of infection due to the age-related immunity decline, known as immunosenescence. Moreover, such patients required more time to heal and hospital stay to get recovered.
  • Increase in need for effective antibacterial treatment options for the geriatric population is expected to drive the demand for the hospital acquired infection treatment (HAI) market
    • According to WHO estimates, the global geriatric population is likely to reach around 2 billion (22% of global population) by 2050, which is currently 566 million.
  • Hospital acquired infections are one the highly frequent adverse events in the health care industry. Presence of unhygienic conditions around and inside the hospital along with improper sterilization techniques applied in the hospitals are increasing the prevalence of hospital acquired infection in low income and middle income countries.
  • According to an article published by Global Antibiotic Resistance Partnership (GARP), more than 190,000 neonatal deaths occurred in India annually due to infection

Get a glimpse of the in-depth analysis through our Report Brochure

Lack of Surveillance Systems for HAIs Boost Market Growth

  • Increasing prevalence of HAIs is because most countries do not have surveillance systems for HAIs, while the countries that have the systems in place often face difficulties with the complexity and lack of standardized criteria for diagnosing the infections. Countries in North America and Europe have surveillance systems for HAI monitoring while countries in Asia Pacific and rest of the world do not have the systems, which makes it difficult to control the outbreak of endemics in these regions.
  • The Healthcare-Associated Infections Surveillance Network (HAI-Net), National Healthcare Safety Network (NHSN), and Japan Nosocomial Infection Surveillance System (JANIS) are some of the surveillance systems working efficiently in developed countries

Multi-drug Resistant Bacteria Making Presently Available Antibacterial Drugs Outdated to Hamper Market

  • Multi-drug resistance is one of the most common causes of failure in treatment for bacterial infection. Bacteria are the only species that can survive even after frequent exposure to one or more antibiotics and develop drug resistance.
  • Moreover, these infections result in higher rate of disability and death compared to the infections that are easily treatable with antibiotics. Multi-drug resistance is affecting the HAI treatment market due to the shift of treatment process.
  • Major types of multi-drug resistant bacteria are methicillin resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococcus (VRE), and multidrug-resistant Mycobacterium tuberculosis (MDR-TB).

 Global Hospital Acquired Infection Treatment (HAI) Market: Competitive Landscape

  • This report profiles major players in the global hospital acquired infection treatment (HAI) market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global hospital acquired infection treatment (HAI) market is highly fragmented, with the presence of a number of international as well as regional players
  • Leading players operating in the global hospital acquired infection treatment (HAI) market
    • Abbott Laboratories
    • Pfizer, Inc.
    • Bayer AG
    • AstraZeneca
    • F. Hoffmann-La Roche Ltd.
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Cipla Inc.
    • GlaxoSmithKline plc
    • Aridis Pharmaceuticals, Inc
    • Astellas Pharma Inc.
    • Daiichi Sankyo, Inc.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company among others.

Expanding operations in future? To get the perfect launch ask for a custom report 

Global Hospital Acquired Infection Treatment (HAI) Market: Key Developments

Key players in the global hospital acquired infection treatment (HAI) market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global hospital acquired infection treatment (HAI) market. A few expansion strategies adopted by players operating in the global hospital acquired infection treatment (HAI) market are:

  • In July 2019, Pfizer Inc. completed acquisition of the privately-held clinical-stage biotechnology company Therachon Holding AG for US$ 340 Mn. Therachon represented the Rare Disease team of Pfizer to develop innovative medicines to treat rare diseases.
  • In December 2018, Pfizer Inc. and GlaxoSmithKline plc entered into an agreement to create a premier global consumer health care company with iconic brands. In 2017, the combined business was approximately US$ 12.7 Bn.

 The report on the global hospital acquired infection treatment (HAI) market discussed individual strategies, followed by company profiles of manufacturers of hospital acquired infection treatment (HAI). The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global hospital acquired infection treatment (HAI) market.

TMR’s report on the global hospital acquired infection treatment (HAI) market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2019 to 2027. The report provides revenue of the global hospital acquired infection treatment (HAI) market for the period 2017-2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global hospital acquired infection treatment (HAI) market during the forecast period.

The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global hospital acquired infection treatment (HAI) market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global hospital acquired infection treatment (HAI) market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global hospital acquired infection treatment (HAI) market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global hospital acquired infection treatment (HAI) market.

The report delves into the competitive landscape of the global hospital acquired infection treatment (HAI) market. Key players operating in the global hospital acquired infection treatment (HAI) market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global hospital acquired infection treatment (HAI) market that have been profiled in this report.

Key Questions Answered in Global Hospital acquired infection treatment (HAI) Market Report

  • What is the scope of growth of product companies in the global hospital acquired infection treatment (HAI) market?
  • What will be the Y-o-Y growth of the global hospital acquired infection treatment (HAI) market between 2019 and 2027?
  • What is the influence of changing trends in technologies on the global hospital acquired infection treatment (HAI) market?
  • Will North America continue to be the most profitable market for hospital acquired infection treatment (HAI) providers?
  • Which factors are anticipated to hamper the growth of the global hospital acquired infection treatment (HAI) market during the forecast period?
  • Which are the leading companies in the global hospital acquired infection treatment (HAI) market?

Research Methodology

A unique research methodology has been utilized by TMR to conduct comprehensive research on the growth of the global hospital acquired infection treatment (HAI) market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary methods referred to by analysts during the production of the global hospital acquired infection treatment (HAI) market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the hospital acquired infection treatment (HAI) market as primary methods.

These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the hospital acquired infection treatment (HAI) market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global hospital acquired infection treatment (HAI) market with accuracy. The study also uses the top-down approach to assess the revenues for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global hospital acquired infection treatment (HAI) market more reliably and accurately.

Regional Segmentation of Hospital Acquired Infection Treatment (HAI) Market

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Global Hospital acquired infection treatment (HAI) Market - Segmentation

Infection Type

  • Urinary Tract Infection
  • Ventilator-Associated Pneumonia
  • Bloodstream Infection
  • Surgical Site Infection
  • Other (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)

Treatment

Antibacterial Treatment

  • Beta-Lactams
  • Quinolones
  • Vancomycin
  • Other

Antiviral Treatment

  • Acyclovir
  • Foscarnet

Antifungal Treatment

  • Amphotericin B
  • Triazoles

Other (Antiparasitic, Antiprotozoal and Anti TB Treatment)

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Store
  • E-Commerce
  • Other

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Hospital Acquired Infection Treatment Market

Buy Now